key: cord-0836711-tmtrqmgz
authors: Lan, Shao-Huan; Lai, Chih-Cheng; Huang, Hui-Ting; Chang, Shen-Peng; Lu, Li-Chin; Hsueh, Po-Ren
title: Tocilizumab for severe COVID-19: a systematic review and meta-analysis
date: 2020-07-23
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.106103
sha: b79e74659bf66617a65515954542d6f2b3addbb6
doc_id: 836711
cord_uid: tmtrqmgz

This systemic review and meta-analysis aimed to assess the efficacy of tocilizumab for the treatment of severe coronavirus disease-2019 (COVID-19). Candidate studies up to May 24, 2020 were identified from PubMed, Cochrane Library, Embase, MedRxiv, and BioRxiv. Treatment outcomes included mortality, risk of intensive care unit (ICU) admission, and the requirement of mechanical ventilation (MV). A total of 7 retrospective studies involving 593 adult patients with severe COVID-19, including 241 in the tocilizumab group and 352 in the control group were enrolled. All-cause mortality of severe COVID-19 patients among the tocilizumab group was 16.2% (39/241), which was lower than that in the control group (24.1%, 85/352). However, the difference did not reach statistical significance (risk ratio [RR], 0.61; 95% confidence interval [CI], 0.31-1.22, I(2) = 68%). In addition, the risk of ICU admission was similar between the tocilizumab and control groups (35.0% vs. 15.8%, RR, 1.51; 95% CI, 0.33-6.78, I(2) = 86%). The requirement of MV was similar between the tocilizumab and control groups (32.4% vs. 28.6%, RR, 0.72; 95% CI, 0.05-10.96, I(2) = 91%). However, these nonsignificant differences between the tocilizumab and control groups may have been the result of the baseline characteristics of the tocilizumab group, which were more severe than those of the control group. Based on low-quality evidence, there is no conclusive evidence that tocilizumab would provide any additional benefit to patients with severe COVID-19. Therefore, further recommendation of tocilizumab for COVID-19 cases should be halted until high-quality evidence from randomized controlled trials is made available.

Since the first case of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- infection identified in the end of 2019, Coronavirus disease-2019 (COVID-19) has become a huge threat for global health [1, 2] . As of May 26, COVID-19 had been confirmed in 5,404,512 patients and resulted in 343,514 deaths [3] . The full spectrum of clinical manifestation of COVID-19 ranges from asymptomatic carrier, mild acute respiratory disease, to severe pneumonia and even acute respiratory distress disease (ARDS) [4] . Although the overall fatality rate was 6.36% [3] , most of the deaths were attributed to severe COVID-19 cases [5] .

COVID-19 is a novel emerging infectious disease, which is associated with a complicated pathogenesis, however, the laboratory evidence of severe SARS-CoV-2 infections suggests that cytokine release syndrome (CRS) plays a crucial pathogenic role [6] [7] [8] . Although many proinflammatory cytokines are involved in the CRS, interleukin-6 (IL-6) is the most important one although it was also found to be a poor prognostic factor [9, 10] . Anti-IL-6 agents have been proposed as one of promising treatment regime for COVID-19 [11] [12] [13] . In fact, tocilizumab is a humanized monoclonal antibody, which can target both membrane-bound and soluble forms of the IL-6 receptor, and several studies have evaluated its efficacy for the treatment of severe COVID-19 [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . In one series of 100 patients with severe COVID-19 pneumonia complicated with ARDS and hyper-inflammatory syndrome [22] , tocilizumab use showed a rapid and sustained response, and also associated with significant clinical improvement. In another study by Ramaswamy et al, although tocilizumab treated patients displayed higher levels of biomarkers (CRP and IL-6) indicative of cytokine storm at the initial presentation, tocilizumab still provided a short-term survival benefit [18] . However, no consistent results were reported among these studies comparing tocilizumab and other treatment regime for COVID-19. Therefore, we conducted this meta-analysis to investigate the impact of tocilizumab on the mortality of patients with COVID-19.

All candidate studies were initially identified by conducting a systematic review of databases, namely PubMed, Cochrane Library, Embase, MedRxiv and BioRxiv until May 24, 2020 by using the following terms: "tocilizumab," "atlizumab," "actemar," "roactemra," "sarilumab," "kevzara," "siltuximab," "sylvant," "CNTO-328," "SARS-CoV-2," "coronavirus," "nCoV," "pneumonia," "corona-virus," "2019 nCoV," and "COVID-19,"

Further detail regarding Search strategy is given in the Supplementary Data.

Only studies that compared the clinical efficacy of anti-IL-6 and its comparators for the treatment of COVID-19, and explicitly reported at least one of the outcomes of interest such as all-cause death, intensive care unit (ICU) admission and requirement of mechanical ventilation (MV) were included. Exclusion criteria were as follows: (1) case reports, (2) single arm studies, (3) studies that did not report outcomes for tocilizumab in COVID-19, (4) studies that did not compare the outcomes for tocilizumab compared to the placebo or control, 

Statistical analysis was conducted using the software Review Manager, version 5.3. The degree of heterogeneity was evaluated with the Q statistic generated from the  2 test. The proportion of statistical heterogeneity was assessed using the I 2 measure. Heterogeneity was defined as significant when the P value was less than .1 or I 2 more than 50%. A fixed-effects model and a random-effects model were applied when data were considered as homogenous or heterogeneous, respectively. The pooled risk ratio (RR) and 95% confidence intervals (CI) were calculated, and a P value of <0.05 was considered as statistically significant.

The search program initially yielded 358 references, subsequently, 272 articles were screened after excluding 86 duplicated articles. Finally, 7 articles were identified for full-text review for eligibility after excluding the remaining 265 articles by title and abstract. In total, only 7 retrospective studies [14] [15] [16] [17] [18] [19] [20] were designed to compare the clinical efficacy of tocilizumab and its comparators in the treatment of patients with SARS-CoV-2 infections were enrolled in this meta-analysis ( Figure 1 and supplemental data). Overall, this meta-analysis involved a total of 593 patients, including 241 in the tocilizumab group and 352

in the control group. The characteristics of included study and patients are shown in table 1 and 2. Except for one multicenter study [18] , the remaining 6 were single-center studies [14] [15] [16] [17] 19, 20] . Three of them were conducted in Italy [14, 15, 17] , and two each in France and US [18, 20] . Only two studies [19, 20] had matched study and control group in terms of age, sex and disease severity. Except for one study [20] that did not report the frequency of administering tocilizumab, three studies [14, 17, 19] used tocilizumab once, one [15] used twice and the remaining two [16, 18] used both once and twice. The fixed dose of 400 mg or 8 mg per kg was the most commonly reported regimen of tocilizumab. In one study, Capra et al [14] also used subcutaneous injection of tocilizumab of 324 mg for 27 patients. Because all included studies were retrospective observational trials, the risk of bias was assessed using the Newcastle-Ottawa Scale [26] . The quality assessment score of each study was 6, indicating high risk of bias for all the 7 studies.

The pooled analysis of the 7 enrolled studies [14] [15] [16] [17] [18] [19] [20] revealed that the all-cause mortality of patients with COVID-19 in tocilizumab group was 16.2% (39/241), which was lower compared to the control group (24.1%, 85/352). However, the difference did not reach statistical significance (RR, 0.61; 95% CI, 0.31-1.22, I 2 = 68%, Figure 2 ). Sensitivity analysis after deleting an individual study successively revealed the same findings. Similar findings were observed in the study conducted in Italy (RR, 0.81; 95% CI, 0.07-9.75, I 2 = 87%) and US (RR, 0.78; 95% CI, 0.51-1.20, I 2 = 0%). However, both studies in France showed that tocilizumab group was associated with a lower mortality rate compared to control group (RR, 0.44; 95% CI, 0.22-0.89, I 2 = 0%).

Five studies [15] [16] [17] [18] [19] reported the rate of ICU admission, and the pooled analysis showed a similar risk of ICU admission between tocilizumab and control groups (35.0% vs 15.8%, RR, 1.51; 95% CI, 0.33-6.78, I 2 = 86%, Figure 3 ). Three studies [16, 18, 19] reported the requirement of MV, and the pooled analysis revealed similar risk between tocilizumab and control groups (32.4% vs 28.6%, RR, 0.82; 95% CI, 0.14-4.94, I 2 = 91%, Figure 4 ).

To the best of our knowledge, this is the first meta-analysis that investigated the effect of tocilizumab on the clinical outcomes of patients with severe COVID-19. Based on the analysis of 7 retrospective studies [14] [15] [16] [17] [18] [19] [20] , we found that tocilizumab could not provide any additional benefit for the clinical outcomes of severe COVID-19. Although the mortality rate of patients treated with tocilizumab was lower than those of the control group, the difference did not reach statistical significance. Only the subgroup analysis of two studies [16, 19] conducted in France showed significant difference in the mortality rates between tocilizumab and control groups. Overall, the mortality rate for tocilizumab treated patients with COVID-19 of these 7 included studies [14] [15] [16] [17] [18] [19] [20] ranged from 3.2% to 38.6%, most probably reflects the "quality of care" as a whole including surge capacity of ICU as it parallels the number of available beds for ICU despite the fact that dosage and population characteristics might play a role. This finding was consistent with several single arm studies [21] [22] [23] [24] . In one open-label prospective study involving 51 patients with severe COVID-19 pneumonia and received tocilizumab in Milan, Italy, 14 (27%) patients had died, indicating higher mortality rate among mechanical ventilated patients [21] . Another prospective study involving 100 patients with COVID-19 and ARDS requiring ventilatory support in Brescia, Italy, in which tocilizumab was administered at a dosage of 8 mg/kg by using two consecutive intravenous infusions 12 h apart, and an optional third infusion based on clinical response, showed that the mortality was 20% (n = 20) [22] . Another pilot prospective open and single-arm multicenter study of 63 patients with severe COVID-19 demonstrated that the overall mortality was 11% and tocilizumab administration within 6 days from admission was associated with an increased likelihood of survival (HR: 2.2; 95%CI, 1.3-6.7, P <0.05) [24] . One small study involving 25 patients showed that the mortality rate was only 12% (n = 3) [23] . In addition to all-cause mortality, we found that the risk of ICU admission and the need of MV were similar between tocilizumab and control groups. In summary, tocilizumab add-on for patients with severe COVID-19 was not associated with a better treatment outcome compared to those without tocilizumab treatment.

However, our findings should be interpreted cautiously. The baseline characteristics and disease severity of the study and control groups were not matched in several included studies (table 2). In Klopfenstein et al's study [16] , tocilizumab group had a higher Charlson comorbidity index, indicating higher severity and worse survival compared to control group (all P < 0.05). In Quartucciol et al's study [17] , tocilizumab group was relatively older and had higher levels of CRP and IL-6 compared to control group. In Ramaswamy et al's study [18] , tocilizumab treated group had higher levels of biomarkers, higher early warning scores at initial symptom manifestation and greater physiologic instability during hospital stay compared to control group. Although initial univariate comparison showed the similar risk of death between study and control groups (14.3% vs 12.3%, P = 0.81), further multivariate analysis found that tocilizumab was associated with 75% reduction in the risk of in-hospital death compared to control group (hazard ratio, 0.25; 95% CI, 0.07-0.90) [18] . In Roumier et al's study [19] that matched tocilizumab and control group for age, gender and disease severity using the inverse probability of treatment weighted methodology, tocilizumab significantly reduced the requirement of subsequent MV (weighted odds ratio: 0.42; 95% CI, 0.20-0.89). Although Wadud et al's study [20] tried to match two groups in terms of age, sex, body mass index, and a score for the diagnosis of reactive hemophagocytic syndrome (HScore) calculated using inflammatory markers (ferritin, triglycerides, aspartate aminotransferase and fibrinogen) as close as possible, however, tocilizumab group still had higher average HScore, and higher levels of IL-6, triglycerides, AST, and ferritin when compared to the control group (all P < 0.0001). Even under this condition, mortality rate remained lower in tocilizumab group compared to control group (38.6% vs 52.0%, P < 0.00001). All of the above findings highlight that tocilizumab group had more severe clinical outcomes compared to the control group and may explain why there is no additional benefit of tocilizumab was found in this meta-analysis.

The safety issues should be another concern while tocilizumab was used for patients with severe COVID-19. Only one study in this meta-analysis reported the adverse event in patients administered with tocilizumab. In Quartucciol et al's study [17] , 42.9% (18/42) experienced bacterial superinfection, but none in the control group. This was consistent with Kimming et al's study [27] , in which, tocilizumab administration was independently associated with the presence of secondary bacterial infections (Odds ratio: 3.960; 95% CI, 1.351-11.607, P =0.033). Additionally, in Morena et al's study [19] , the most common adverse event included increase of hepatic enzymes (29%), thrombocytopenia (14%), and serious bacterial and fungal infections (27%). In Toniati et al's report involving 100 patients [22] , two patients developed septic shock and died, one had gastrointestinal perforation requiring urgent surgery. Although Alattar et al reported that the majority (92%) of patients experienced at least one adverse event in a small study involving 25 patients and the most prevalent adverse events were anemia (16, 64%), alanine aminotransferase rise (11, 44%) , and QT interval prolongation (5, 20%). However, there is no conclusive evidence that explains which of these adverse effects were directly related to tocilizumab therapy [23] . Overall, no conclusion can be derived from these findings, and more studies are needed to assess the tolerability of tocilizumab in patients with COVID-19.

In addition, this meta-analysis has several limitations that should be addressed. First, all of included studies were not randomized controlled trials and the reported clinical characteristics of the patients were not homogeneous. In addition to two studies that tried to match the study and control group in terms of disease severity, tocilizumab groups consistently had more severe symptoms compared to control groups in most of the studies in this meta-analysis. Second, various treatment regimens including the dosage and frequency of tocilizumab in the study and the anti-viral regimen groups were applied in the studies. In addition, although the delay between onset of disease and treatment appears as a very important variable, it was not reported in all of selected studies. However, the timing of tocilizumab administration could affect the outcome of patients with severe COVID-19.

Third, the number of studies and patients were small, which may result in type II statistical errors. Thus, further large scale randomized controlled study is required to clarify our findings.

In conclusion, based on low-quality evidence, there is no suggestion that tocilizumab would provide any additional benefit for patients with severe COVID-19. Many issues, such as which population can benefit from tocilizumab, the appropriate timing, dosage and regimen of tocilizumab, and the risk of adverse effects remain unclear. Further recommendation of tocilizumab should therefore be halted until high-quality evidence from ongoing randomized trials for tocilizumab (ChiCTR2000029765; NCT04320615), and other anti-IL-6 agentssarilumab (NCT04315298; NCT04324073) and siltuximab (NCTNCT04329650), is made available.

Funding: None.

Competing Interests: None declared. 

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Global coronavirus disease 2019: What has daily cumulative index taught us?

Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths

Clinical characteristics of coronavirus disease 2019 in China

Cytokine release syndrome in severe COVID-19

COVID-19: A new virus, but a familiar receptor and cytokine release syndrome

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

A cluster of health care workers with COVID-19 pneumonia caused by SARS-CoV-2

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality

Rational use of tocilizumab in the treatment of novel coronavirus pneumonia

Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia

Tocilizumab for treatment of severe COVID-19 patients: Preliminary results from SMAtteo COvid19 REgistry (SMACORE)

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care

Off-label real world experience using tocilizumab for patients hospitalized with COVID-19 disease in a regional community health system: A case-control study

Interleukin-6 blockade for severe COVID-19. medRxiv

Improved survival outcome in SARs-CoV-2 (COVID-19) acute respiratory distress syndrome patients with tocilizumab administration

Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy

Tocilizumab for the treatment of severe coronavirus disease 2019

Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections